Charles River Laboratories announced today that it has completed the previously announced acquisition of MPI Research.
MPI Research is a premier non-clinical contract research organization (CRO) providing comprehensive testing services to biopharmaceutical and medical device companies worldwide. Acquiring MPI will enhance Charles River’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum.
James C. Foster, Chairman and Chief Executive Officer of Charles River Laboratories, commented, “We are pleased to welcome the exceptional team at MPI Research to the Charles River family. The addition of MPI’s scientific expertise, high-quality services, and complementary capabilities will enable us to enhance the support we can provide to clients, as they address the complex challenges of drug discovery and early-stage development. The acquisition of MPI also enhances our ability to achieve our long-term growth goals by building scale to meet current and future demand, and by expanding our biotechnology client base, the fastest-growing market segment.”
Areas of Expertise
MPI offers high-quality services and complementary capabilities including:
- Ototoxicity testing
- Abuse liability
- Surgical services and medical device development
- Ocular toxicology
- Infectious disease models for vaccine safety and efficacy studies
- Cell and gene therapy
Located in Mattawan, Michigan, it is the world’s largest nonclinical facility (> 1M square feet) with dedicated vivarium space (500+ animal rooms), bioanalytical/analytical laboratory space, and 4 surgical suites. The MPI Research portfolio complements Charles River’s services by providing both GLP and non-GLP studies.
Behind every patient stands thousands of scientists and researchers working together to develop life-saving treatments. Every day, each of us plays a critical role in making a difference in the quality of people’s lives.